Que penser de tous ces essais de non-inferiorite pour demontrer la securite cardiovasculaire des nouveaux medicaments antidiabetiques?

Scheen, Andre

Article (Scientific journals)

Scheen, Andre

2015 • In Revue Médicale Suisse, 11 (483), p. 1515-6

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/187450

PubMed
26502576

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

RMS_AS edito 2015.pdf

Publisher postprint (439.07 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

sécurité cardiovasculaire; diabète de type 2; GPL-1; Gliflozin

Disciplines :

Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, Andre ; Université de Liège - ULiège

Language :

French

Title :

Que penser de tous ces essais de non-inferiorite pour demontrer la securite cardiovasculaire des nouveaux medicaments antidiabetiques?

Alternative titles :

[en] In Process Citation

Publication date :

2015

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Special issue title :

Thérapeutique

Volume :

Issue :

483

Pages :

1515-6

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 30 October 2015

Statistics

Number of views

37 (1 by ULiège)

Number of downloads

137 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Scheen, A.J., Rev Med Suisse
Head, S.J., Kaul, S., Bogers, A.J., Kappetein, A.P., Eur Heart J
Scheen, A.J., Rev Med Suisse
Scheen, A.J., Charbonnel, B., Diabetes Metab
Scheen, A.J., Paquot, N., Rev Med Suisse